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Editor's Note
This newsletter addresses a
number of critical issues for mem-
bers of the Council on Thrombosis.
Dr Thomas Deuel reviews a meeting
with Dr Claude Lenfant, director of
NHLBI, that occurred during the
December 1994 meeting of the
American Society of Hernatology.
The meeting with Dr Lenfant fo-
cused on ways to improve commu-
nication between our council and the
NIH. Dr Deuel also gives an Update
on the important ongoing work with
respect to the future of vascular
biology and its role in the AHA.
There is serious consideration about
consolidation of the Council on
Thrombosis with the Council on
Arteriosclerosis and the Working
Group on Vascular Biology. Dr
Samuel Rapaport, incoming chair of
the Thrombosis Council, discusses
this in his report on page 2.
Drs Pan Ganguly (Blood) and David
Robinson (Heart) have replaced
Dr Carol Letendre äs our liaison with
the NHLBI. Dr Ganguly's report
covers new initiatives and reviews
recent changes in funding guide-
lines. Dr Kenneth Mann reviews the
Status of the AHA grant System and
discusses a number of approved
and pending changes. Dr Jack
Hawiger reports that our Journal
Arteriosclerosis, Thrombosis, and
Vascular Biology is doing well.
This issue of the newsletter also
includes a new feature, an invited
review of a topical area. Dr Frits
Rosendaal from the Departments of
Clinical Epidemiology and Hernatol-
ogy, Leiden, The Netherlands, has
contributed a review entitled "Resis-
tance to Activated Protein C by
Factor V Leiden: Clinical Implica-
tions." Finally, there is a review of
the programs for the Council on
Thrombosis at the 1995 ASH
meeting and the 1996 AHA meet-
ings along with a report on the
budget for fiscal year 1995-1996.
Edwin G. Bovill, MD
Report From the Chair
Report From Thomas F. Deuel, MD, Immediate Fast Chair
Two most important events need your closest atten-
tion.
During the American Society of Hernatology Meeting in
December, Sam Rapaport and l met for an hour and a
half with Claude Lenfant, director of the NHLBI. The
meeting was very productive. We primarily discussed
ways in which the Council on Thrombosis might enhance
Communications with Dr Lenfant and the NHLBI and
mechanisms to maintain the highest levels of communi-
cation. Dr Lenfant expressed great interest in the
activities of the Council on Thrombosis and the Commu-
nity that it represents. He invited our input into all issues
related to the activities of the NHLBI. We discussed
changes in the focus of the Council on Thrombosis that
have evolved over the past several years and empha-
sized that many investigators within the council are now
focusing on issues of vascular biology, atherosclerosis,
and cardiovascular disease äs the natural outgrowth of
research in hemostasis and thrombosis. The vigor and
energy of these investigators and the importance of their
contributions to an understanding from a variety of
perspectives of phenomena within the blood vessel wall
was stressed. We emphasized the importance of
recognizing within NHLBI the extent to which contribu-
tions of the thrombosis Community could overlap the
activities of the Vascular Biology Program of the Division
of Heart and Vascular Diseases. In response, Dr
Lenfant agreed to appoint Dr David Robinson, director of
the Vascular Biology Program, äs an additional liaison to
the Council on Thrombosis. Thus, both our present
liaison, Dr Pan Ganguly, leader of the Thrombosis and
Hemostasis Scientific Research Group within the
Division of Blood Diseases and Resources, and Dr
Robinson will now work with the council. This is a
wonderful commitment to us, and we enthusiastically
look forward to working with both of them. Sam
Rapaport and l hope to meet periodically with Dr Lenfant
to maintain a fruitful, continuing interaction between the
Council on Thrombosis'and the NHLBI.
The second issue of major importance to the Council
on Thrombosis is the future of vascular biology in the
AHA. Sam Rapaport, Ralph Nachman, and l repre-
sented the Council on Thrombosis on the Task Force on
Intercouncil Cooperation, a committee appointed by Dr
James Moller, President of the AHA during 1993-1994, to
find ways to integrate activities of the Working Group on
Vascular Biology, the Council on Thrombosis, and the
Council on Arteriosclerosis.
The Working Group on Vascular Biology was formed in
1991 to address interests related to vascular biology, but
its activities will cease in mid-1997. The gain to the
Council on Thrombosis of merging with the working
group and the Council on Arteriosclerosis would be a far
larger council with far greater impact within the AHA and
far greater opportunities to influence the content of
meetings äs well. Coordinated programs and activities
can only enhance our visibility and strength within the
AHA and will better serve its mandates for consolidation
of councils and coordination of activity. Such a union
would also help emphasize our areas in the research
Community. We plan to have a separate meeting in
addition to the AHA meeting that will represent all three
groups; this will be a highly visible and important meet-
ing. However, it will not replace the importance of the
contributions to the annual meeting.
This consolidation of the Councils of Thrombosis and
Atherosclerosis with the Working Group on Vascular
Biology was discussed at great length at the meeting of
the Executive Committee in May. It was concluded that
such a consolidation was highly desirable and consistent
with the long-range goals of the council. It was also
stressed that the needs of the diverse interests of
council members had to be met in füll in order to consoli-
date the three groups. The Executive Committee
unanimously voted to bring this matter to füll discussion
at the November meeting of the council with the goal of
a vote of the council members to follow.
The opportunities for advancing the cause of
thrombosis are striking but can be done only if members
of the council are enthusiastic and utmost consideration
is given to our best interests. l invite your comments
and very much urge each of you to write.
In ciosing, l thank the Council on Thrombosis for the
privilege to serve äs chair. It has been a most rewarding
experience. l look forward to helping Sam Rapaport and
Bob Rosenberg, the new chair and vice-chair, in any way
possible.
Report From Samuel I. Rapaport, MD,
Chair
In July of this year l succeeded Dr Deuel äs chair of
the Council on Thrombosis. As recommended at the
May 1995 meeting of the Executive Committee, l am
proceeding with plans for a proposed merger of the
Councils on Thrombosis and Arteriosclerosis to be
followed by a proposal from a merged council to the
Working Group on Vascular Biology to incorporate their
interests within a combined Council on Arteriosclerosis,
Thrombosis, and Vascular Biology.
In August l wrote a letter to all present and past
members of the Executive Committee (since 1988) to
summarize the background of the proposed merger and
the reason why it is necessary for the Executive Com-
mittee to decide without delay at its meeting in Anaheim
this November on whether to proceed with the merger
with the Council on Arteriosclerosis. A copy of this letter,
which includes how to contact me by regulär mail, fax,
and e-mail, follows to inform all council members of how
we got to where we are now.
There are many advantages to a proposed combined
larger council, but there will be issues to resolve äs a
merger with the Council on Arteriosclerosis proceeds. If
you have specific feelings about the proposal or issues it
raises, l invite you to send them to me before the
November meeting of the Executive Committee.
Since this is our "off year" at the AHA Scientific
Sessions, l know that many of you will not be present at
the meeting. For those of you who will be there, please
make a special effort to attend the business meeting of
the council, which will be heid at noon on Monday,
November 13.
TO: Present and Recent Past Members of the
Executive Committee of the Council on
Thrombosis
FROM: Samuel l. Rapaport, Chairperson, Council
on Thrombosis
SUBJECT: Proposed Merger With Council on
Thrombosis and Vascular Biology Working
Group
l am writing for two purposes:
(1) To inform you of the Status of considerations for a
proposed merger of the Councils on Arteriosclerosis and
Thrombosis to be followed by a proposal from the
merged council to the Vascular Biology Working Group
to incorporate their interests within a combined Council
on Arteriosclerosis, Thrombosis, and Vascular Biology.
(2) To seek advice in defining issues in this regard that
need advance thought before the forthcoming Council on
Thrombosis Executive Committee meeting next Novem-
ber at the AHA Scientific Sessions in Anaheim.
Two years ago the Counci! Affairs Committee and the
Steering Committee of the AHA commissioned a task
force to examine the current structure of the Councils on
Arteriosclerosis and Thrombosis, assess the relationship
of vascular biology and the Vascular Biology Working
Group of AHA to these councils, and develop options to
integrale and enhance the functions and activities of all
three groups. Drs Scott Grundy and Ken Mann were
appointed by AHA to serve äs cochairs of the task force.
Membership included the chairpersons, vice chairper-
sons, and immediate past chairpersons of the two
councils (Drs Deuel, Rapaport, and Nachman for the
Council on Thrombosis; Drs Small, Grundy, and St. Clair
forthe Council on Arteriosclerosis) and Dr Victor Dzau,
chairperson of the Vascular Biology Working Group.
After long discussions at three meetings of pros and
cons, the task force recommended that the two councils
and the working group be integrated into a new scientific
council structured to accommodate the overlapping
interests of the participating groups. Dr Deuel and l, äs
your representatives on the task force, concurred fully
with this recommendation (Dr Nachman was not present
at the meeting). We believe that the bringing into a
single AHA "scientific tent" of investigators interested in
diverse aspects of the pathogenesis and treatment of
thrombotic disorders would have many advantages. A
new scientific council created out of the existing Coun-
cils on Arteriosclerosis and Thrombosis and the Working
Group on Vascular Biology should have a greater say in
the structure of the scientific program at the annual
national meeting in November. It would support an
expanded scope and influence of our Journal Arterioscle-
rosis, Thrombosis, and Vascular Biology. Moreover, the
new amalgamated council should have the critical mass
needed to Sponsor a yearly stand-alone meeting on
vascular biology in the spring of the year. Indeed, at the
instigation of the task force, a scientific meeting that
could serve äs a prototype for future spring symposia
will be held in Salt Lake City on February 18-20, 1996
[see announcement on page 13]. l hope that many of
you will participate in this meeting.
After the last meeting of the task force in April 1995,
Drs Grundy and Deuel wrote a draft memorandum from
the task force to the Councils on Arteriosclerosis and
Thrombosis and the Working Group oin Vascular Biology
proposing the creation of an enlarged and integrated
council involving the three groups. This memorandum
was reviewed at the May meeting of the Executive
Committee of the Council on Thrombosis, which was
held in San Diego in conjunction with the clinical meet-
ings. At that meeting it was moved, seconded, and
carried that the Council on Thrombosis pursue the
feasibility of an amalgamation äs described in the
memorandum. Since a number of members of the
Executive Committee were unable to attend this May
meeting, l am enclosing with this letter a copy of the
memorandum.
In June 1995 Dr Grundy, äs cochair of the task force,
reviewed the task force memorandum at a meeting of
the Council Affairs Committee. A proposed merger of
the Councils of Arteriosclerosis and Thrombosis evoked
no Substantive comment from other council chairs
present at that meeting. Subsequently, Dr Rodman D.
Starke, Senior Vice President, Office of Scientific Affairs,
advised Dr Grundy, äs chairperson of the Council on
Arteriosclerosis, and me, äs the incoming chairperson of
the Council on Thrombosis, that the next step in moving
forward a merger of the Councils on Arteriosclerosis and
Thrombosis would be a vote in favor of such a merger
from the Executive Committee of each council.
Dr Grundy informs me that the Executive Committee
of the Council on Arteriosclerosis met earlier this month
and enthusiastically endorsed the recommendation of
the task force that the Councils on Arteriosclerosis and
Thrombosis merge and jointly make a proposal for
creation of a new scientific council that will incorporate
vascular biology. The Executive Committee of Arterio-
sclerosis also recommended that this larger council have
three subsections identified äs (a) lipid and lipoprotein
metabolism, (b) thrombosis, and (c) vascular biology and
that the Executive Committee of the new council be
composed primarily of representatives of these three
subsections.
Working Groups of AHA have a five-year term, which
for the Working Group on Vascular Biology expires in
1997. Therefore, the Vascular Biology Working Group
must soon decide whether their continuing activities
within AHA are best served within a combined Arterio-
sclerosis, Thrombosis, Vascular Biology Council. At the
June meeting of the Council Affairs Committee, chairper-
sons of several other councils expressed interest in the
future of the Vascular Biology Working Group. A real
possibility exists that the working group will receive
within the next several months competing specific
proposals to affiliate with other AHA councils, eg,
Circulation and High Blood Pressure Research.
Since the Executive Committee of the Council on
Arteriosclerosis has approved a merger with the Council
on Thrombosis and since such a merger must precede a
timely preparation of a joint proposal to the Vascular
Biology Working Group, l will call for a motion to merge
the two councils at the next meeting of our Executive
Committee in November at Anaheim. Because of the
importance of this motion, l urge all present members of
the Executive Committee to attend the meeting in
November. Present plans are for our Executive Commit-
tee to meet jointly with the Executive Committee of the
Arteriosclerosis Council at a luncheon meeting on
Sunday, November 12, and separately later that after-
noon.
l apologize for the length of this letter, but l wanted
you to be fully informed of how we got to where we now
are. Again, l invite your comments on issues related to
the proposed amalgamation with the Council on Arterio-
sclerosis and the Vascular Biology Working Group. You
can reach me äs follows:
Samuel l. Rapaport, MD
UCSD Medical Center (8423)
200 West Arbor Drive
San Diego, CA92103
Telephone No: (619) 543-3552
Fax No: (619) 543-3231
e mail: SRAPAPORT@ucsd.edu
Invited Review
Resistance to Activated Protein C by Factor V Leiden: Clinical Implications
Until recently, no abnormality of hemostasis could be
found in over 80% of patients with familial thrombophilia.
The conditions detectable were primarily deficiencies of
protein C, protein S, and antithrombin. Among all
patients with venous thrombosis these deficiencies are
present in less than 5%.1i2This has changed dramati-
cally with the reports on resistance to activated protein C
(APC).
Protein C is a major natural inhibitor of coagulation. It
is activated by the negative feedback system of acti-
vated thrombin and membrane-bound thrombomodulin.
Activated protein C, when the coenzyme protein S is
present, inhibits clotting by inactivating the procoagulant
factors Va and Villa. Addition of APC to plasma in vitro
therefore lengthens the clotting time.The first report on
APC resistance showed that some individuals with
thrombophilia do not exhibit the expected Prolongation of
the clotting time; ie, they are resistant to APC.3 It has
been shown that this resistance is the result of a muta-
tion in the factor V gene (factor V Leiden), a single-base
Substitution of adenine for guanine, corresponding to the
cleavage site of protein C.4
Two tests are available to diagnose this abnormality, a
clotting test for APC resistance and a DNA test (poly-
merase chain reaction [PCR]) for the mutation. The
clotting test consists of performing two APTTs, one
before and one after adding APC to the test plasma.
The ratio of the two, preferably normalized to the APTT
of normal pool plasma, is the APC-sensitivity ratio, which
is reduced in APC resistance. This clotting test cannot
be used for patients who are taking warfarin. The DNA
test is based on a PCR amplification, showing loss of an
Mnll restriction site at position 1691 when the Substitu-
tion of adenine for guanine is present.
APC resistance increases the risk of venous
thrombosis about eightfold and thereby is a risk factor
for thrombosis of similar strength äs protein C and
antithrombin deficiency.5·6 The rare patient with homozy-
gous factor V Leiden has a risk of thrombosis that is
increased up to 100-fold.7The risk in absolute terms is
highly dependent on age: in those under age 30, the risk
for a first thrombotic event is about 1 per 10,000 per
year for those without factor V Leiden and still only 6 per
10,000 per year for heterozygous carriers. For those
aged 50 and older, the risk is 2 per 10,000 per year for
those with the normal genotype and over 15 per 10,000
per year for carriers of the mutation. For homozygous
carriers, the risk is one to several percentage points per
year.
There are other modifying factors besides age. First,
risk estimates given apply to those without malignancy,
in which circumstance the risk may be higher. Second,
oral contraceptives appear to increase the risk synergis-
tically with factor V Leiden: for women aged 15 to 49
who carried the mutation and used oral contraceptives,
the risk of venous thrombosis is approximately 30 per
10,000 per year, ie, at least a 30-fold increase.8 These
risk estimates are based on studies conducted in the
Netherlands, where there is an estimated overall risk of
first thrombosis of about 2 in 10,000 per year. Risk of
thrombosis with and without factor V Leiden may vary
between populations.
It is becoming more clear that the presence of several
risk factors is needed to manifest thrombosis. This is
illustrated by the reports in individuals with more than
one genetic defect, eg, protein C deficiency and APC
resistance, in whom the risk of thrombosis is greatly
increased.9These data may help to explain previously
reported differences in clinical penetrance of
thrombophilic defects between and within families.10·11
Whereas it is ciear that factor V Leiden is the most
common determinant for deep-vein thrombosis, its role
in arterial thrombosis remains unclear. Some reports
suggest that it increases the risk of myocardial infarction
äs well äs ischemic stroke, whereas other studies found
no association.12'14 Although it may seem logical that a
risk factor for deep-vein thrombosis would also increase
the risk of pulmonary embolism, no studies have specifi-
cally examined this.
It is still unclear whether factor V Leiden is the etiology
for all cases of hereditary APC resistance.15 If there are
cases of APC resistance caused by other defects,
however, these are very rare. Most discrepancies
between the clotting test and the DNA test appear to
result from laboratory problems with the clotting as-
say.16·17 It therefore seems advisable to perform the DNA
test äs a first screen rather than the clotting test and
certainly not to base a diagnosis solely on the clotting
test.
The most remarkable feature of APC resistance by
factor V Leiden is its high prevalence. It is found in about
50% of patients with familial thrombophilia, in 20% of all
patients with a first deep-vein thrombosis, and in 3% to
5% of the general population.4~6This leads to much wider
implications than the rare deficiencies of protein C,
protein S, and antithrombin because so many more
individuals are affected.
Most importantly, in testing for factor V Leiden, there is
little reason to think in terms of "familial" thrombophilia.
For deficiencies of protein C, protein S, and antithrom-
bin, even if diagnostic tests are limited to those with a
clear family history and no known explanation for the
thrombosis, the probability of a positive test is about
10%. For APC resistance this probability is already twice
äs high if we would just test all patients with thrombosis.
Indiscriminate screening of the total population would
still yield about a 5% incidence of carriers. Very few
would advocate such a screening policy; still, the ex-
ample forces us to reexamine the benefits of diagnostic
testing.
Generally there are two possible benefits of a diagnos-
tic test: first, the psychological benefit of knowing, and
second, the medical benefit of subsequent preventive
interventions.The former may differ from case to case;
obviously, this is more important in families that have
suffered from unexplained thrombosis for many genera-
tions. The benefit may be less obvious for a single
patient with a first thrombosis, and the psychological
benefit may then reside mainly with the physician.
Because of the synergistic effect of APC resistance
and oral contraceptives, it is advisable to test for the
mutation before prescribing oral contraceptives in
women with a suspected family history of thrombosis
and in all women who experience venous thrombosis
while using oral contraceptives. The decision of whether
or not to prescribe oral contraceptives in a carrier may
be difficult since all other reversible methods of contra-
ception have a considerably higher risk of unwanted
pregnancies (and subsequent postpartum thrombosis).
The benefit of preventive interventions is mainly to
prescribe short-term anticoagulation in high-risk situa-
tions (eg, surgery, plaster casts, immobilization, and
postpartum periods). Aspirin is not a proven therapy for
venous thrombosis prophylaxis. It seems reasonable to
follow the same clinical policy äs is done with deficien-
cies of protein C and protein S. It is presently unclear
whether patients benefit from long-term therapy with
warfarin. This treatment does carry a well-documented
risk of bleeding of about 3% per year even in dedicated
anticoagulation clinics,18 which is especially relevant in
considering long-term prophylaxis.
Most centers would therefore not prescribe long-term
anticoagulation after parturition in an asymptomatic
patient with a thrombophilic abnormality. Some would
after a first thrombotic event, and most would after
recurrent events. There is less agreement on whether or
not to anticoagulate during pregnancy because of the
need for prolonged treatment with heparin and the risk of
bleeding, although the risk of thrombosis in pregnancy in
thrombophilia is high.19 The high frequency of postpar-
tum thrombosis, which can be prevented by a few weeks
of anticoagulation, justifies short-term anticoagulation
parturition.
Part of the expected benefits paradoxically depend on
the local anticoagulation policy in patients without
thrombophilia: if this is extensive, äs in the Netherlands,
where short-term anticoagulation is prescribed for all
individuals in most high-risk situations (except preg-
nancy and puerperium), there may be little preventive
gain in diagnosing thrombophilia. If anticoagulation is
less widespread, individuals may gain more from a
diagnosis of thrombophilia and subsequent prophylaxis
when indicated.
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Committee and Liaison Reports
Report From the NHLBI
All divisions of the NHLBI—Blood (DBDR), Heart
(DHVD), Lung (DLD), Epidemiology (DECA), and
Extramural (DEA)—have moved to a new location in
Bethesda, Maryland. The Office of the Director, NHLBI,
continues to be located in the main NIH campus. The
Thrombosis and Hemostasis Scientific Research Group
has a new telephone number, 301 -435-0070; fax num-
ber, 301-480-1046; and mail stop code (MSC), 7950.
With the reorganization of the NHLBI, the Division
Advisory Committee has been replaced by the Special
Emphasis Panel (SEP), which is convened äs needed.
The Blood Division SEP met on April 27 and 28, 1995.
The panel reviewed the old initiatives on hold äs well äs
new, timely ideas for possible implementation. The
following is a partial list of ideas that were enthusiasti-
cally recommended for further development. It was
recognized that the budgetary environment may permit
implementation of only the top priority initiatives by the
NHLBI.
• Genetic and other risk factors of thrombosis
• Homing determinants in embryonic and hematopoietic
stem cells
• Identification and characterization of human histocom-
patibility antigens
• Immunogenetics of Inhibitor formation in hemophilia
• Effects of sickle cell disease on the lung
• Thrombopoietin, megakaryocytopoiesis, and platelet
production
• New approaches to improve the function and viability
of platelets
The following are highlights of some of the funding
guidelines being followed at NHLBI at this time. Since
these guidelines may change, investigators considering
submitting a research grant application are urged to call
the appropriate program Office for the latest Information.
Beginning fiscal year 1995, NHLBI has adopted a
more flexible funding plan in that a small amount of
money is allocated to the divisions to fund applications
with innovative ideas of high risk or potential clinical
impact. Applications from young or minority investiga-
tors will also receive consideration for support.
Competitive renewal applications are funded at no
more than 10% higher than the amount of direct costs
awarded for the last year of the preceding project period.
Investigators contemplating a significant expansion of
their research program may consider submitting a new
application. Competitive renewal of FIRST Awards to a
regulär R01 grant is exempt from this budgetary restric-
tion. Future year commitments is usually escalated at
4% per year.
To achieve an overall average project period of 4
years, NHLBI may reduce the duration of grants over a
certain percentile by 1 year.
Program project grants are funded with a set-aside
fund and do not compete with other regulär grants.
However, these grants must meet the budgetary ceiling
for that year. Any investigator contemplating submitting
an application for a program project grant should consult
with the appropriate program person äs soon äs pos-
sible.
A variety of Information about NHLBI programs is now
available through the gopher on Internet at
gopher.nhlbi.nih.gov.port:70. Although the gopher has
been in place only for short time, we are pleased to find
that it is being increasingly used by our Community.
Please contact me at 301-435-0070 if you have any
questions.
Pan Ganguly, PhD
Report From the Research Committee
The good news is that there has been an increase in
the number of funded national Grant-in-Aid applications
on a percentage basis for the AHA. This year, 185 out
of 938 applications were approved forfunding at 19.7%.
This percentage of funding was also achieved in the
thrombosis study section; however, the numbers of
grants received by the thrombosis Community this year
was Iow. Only 40 grants were received compared with a
normal year in which approximately 70 to 80 grants are
received. l would encourage colleagues who are eligible
for a Grant-in-Aid to compete for these awards.
At the last research committee meeting, March 31,
1995, a number of alterations to existing national pro-
grams and a new program called the "AHA Scientist
Development Grant" were approved. These changes
were approved by the Research Program and Evaulation
Committee and the Steering Committee.
A summary of these three proposed grant areas is
provided in the table beginning on page 8. The new
AHA Scientist Development Grant is intended to support
highly promising, beginning scientists in progress toward
independence by encouraging and adequately funding
research projects that can serve to bridge the gap
between completion of research training and readiness
for successful competition äs an independent investiga-
tor. The Scientist Development Grant will be supported
at the level of $65,000 per year with up to 4 years of
funding. The Established Investigator Grant continues
but has been increased in budget to $75,000 per year
and modified to include both salary and project support.
The Grant-in-Aid award is also proposed to be altered to
remove any restrictions from candidacy (such äs those
implemented in the past 2 years to limit access to
beginning investigators). The award value has been
increased to $55,000. Note that renewals will not be
permitted; only newly initiated research projects will be
considered for a Grant-in-Aid.
It is anticipated that these changes will take place in
awards initiated in 1997 based on applications submitted
in 1996.
Kenneth G. Mann, PhD
PROPOSED NATIONAL AHA RESEARCH PROGRAM PORTFOLIO
Summary of Award Characteristics
Approved by Research Committee March 31,1995
Characteristics
Program
Objective
Science
Focus
Disciplines
Faculty Rank
Maximum
Degree
Requirement
Experience
Restrictions
Citizenship
Other
Restrictions
Unique Peer
Review Criteria
Common Peer
Review Criteria
Pl Salary,
Fringes Paid?
Common
Budget Items
AHA Scientist
Development Grant
To fund projects that
will bridge the gap
between research
training & readiness
for competition äs
independent
investigator
El Grant
To support career
development of newly
independent
investigators by
funding projects for
which support has not
been obtained
Grant-in-Aid
To fund distinct,
highiy meritorious,
innovative projects
from independent
investigators
Research broadly related to CV function and disease, stroke, or to
related clinical, basic science, and public health problems
All basic disciplines äs well äs epidemiological and clinical
investigations that bear on cardiovascular and stroke problems
Assistant Professor
(or equivalent)
Associate Professor
(or equivalent)
Professor
(or equivalent)
MD, PhD, DO, or equivalent
No more than 4 years
elapsed since first
faculty appointment
US citizen,
permanent resident
Non-renewable.
Awardees may apply
for El Grant in final
year.
Evidence that award
will promote
independence
At least 4 years but
no more than 9 years
elapsed since first
faculty appointment
US citizen,
permanent resident
Non-renewable.
Prior Eis ineligible.
Awardees may apply
for GIA in final year.
Prior national-level
award(s), evidence of
independence from
mentor
None
US citizen,
exchange visitor,
permanent resident
Awardees may
reapply in final year
for a different project.
Evidence of scientific
independence;
innovative, distinct
nature of proposal
Scientific merit of research proposal; qualifications, relevant experience
and productivity of applicant; relationship to Supervisor; adequacy of
available resources, facilities
Yes, consistent with
% total effort, $ cap
Yes, consistent with
% total effort, $ cap
No
Salaries of technical personnel essential to the project, supplies,
equipment, travel, volunteer subject costs, publication costs, and 10%
institutional indirect costs
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Characteristics
Annual Award
Payment
Components
Total Annual
Award Amount
Award
Duration
Maximum
Total Award
Commitment
Interim
Reporting
Evaluation
AHA Scientist
Development Grant
Up to $30,000 for
Pl salary/fringes.
At least $35,000 for
project.
$65,000 including
1 0% indirect costs
4 years
$260,000
El Grant
Up to $35,000 for
Pl salary/fringes.
At least $40,000 for
project.
$75,000 including
1 0% indirect costs
4 years
$300,000
Grant-in-Aid
Up to $50,000 for
project.
$55,000 including
1 0% indirect costs
3 years
$165,000
Assessment of annual progress reports to include research findings,
abstracts, publications and names of trainees supported (optional for
Scientist Development Grants)
Publications, citations by others, ability to attract ongoing research
funding, faculty advancement, other evidence of career progression,
etc.
* Final decisions concerning award Characteristics will be made
by the Research Committee at its November meeting.
Progress Report on Arteriosclerosis, Thrombosis, and Vascular Biology
It is approximately 4.5 years since a separate editorial
office for Thrombosis was established. During this time,
the Journal has grown, expanding from a bimonthly to a
monthly publication. Its scope has expanded äs well, äs
reflected in the addition of the phrase "vascular biology"
to the title.
The impact of the Journal continues to have a high
ranking according to the Institute for Scientific Informa-
tion (ISI) measurements, and the Journal compares
favorably with the top publications in the field of cardio-
vascular biology and medicine. Among those Journals
categorized by the ISI under the rubric "cardiovascular
System," Arteriosclerosis, Thrombosis, and Vascular
Biology was ranked fourth with an impact factor of 5.3 in
the latest Scientific Citation Index. What is of great
significance to the Council on Thrombosis is that our
Journal outranks those of its competitors that are specifi-
cally directed to the field of thrombosis. For example, in
the 1993 rankings (the latest available), Thrombosis and
Haemostasis ranked sixth and Thrombosis Research
ranked 36th. The thrombosis portion of the Journal
continues to develop and is attracting quality submis-
sions. The number of thrombosis-related submissions to
the Vanderbilt editorial Office alone grew 25% in 1994,
which followed 22% and 38% increases in 1993 and
1992, respectively. Plans for the Journal currently being
implemented include future publication of minireviews on
focused topics of current research.
We have been trying to improve the function of our
editorial Offices. Statistics for the Thrombosis editorial
office show that 43.6% of 1994 manuscripts were
accepted, 43.6% were rejected, and 12.7% remain
under revision. The interval from Submission of all
manuscripts to first decision was 6.9 weeks, while for
accepted papers, the interval from Submission to final
decision was 21.0 weeks. The average priority rating for
manuscripts ultimately accepted for publication was 2.7.
Examples of recently published thrombosis articles in
Arteriosclerosis, Thrombosis, and Vascular Biology are
listed below:
Platelet Biology
• AM Vicari, ML Monzani, F Pellegatta, P Ronchi,
L Galli, F Folli. Platelet calcium homeostasis is
abnormal in patients with severe arteriosclerosis
(vol 14, no 9)
• PS Tsao, G Theilmeier, AH Singer, LLK Leung, JP
Cooke. L-Arginine attenuates platelet reactivity in
hypercholesterolemic rabbits (vol 14, no 10)
• C Legrand, V Morandi, S Mendelovitz, H Shaked,
JR Hartman, A Panet. Selective Inhibition of platelet
macroaggregate formation by a recombinant hep-
arin-binding domain of human thrombospondin (vol
14,no 11)
• J-C Ruf, J-L Berger, S Renaud. Platelet rebound
effect of alcohol withdrawal and wine drinking in rats:
Relation to tannins and lipid peroxidation (vol 15, no
1)
• A Notarbartolo, G Davl, M Averna, CM Barbagallo, A
Ganci, C Gianmarresi, FP La Placa, C Patrono.
Inhibition of thromboxane biosynthesis and platelet
function by simvastatin in type lla
hypercholesterolemia (vol 15, no 2)
• E Malle, A Ibovnik, HJ Leis, GM Kostner, PFJ
Verhallen, W Sattler. Lysine modification of LDL or
lipoprotein(a) by 4-hydroxynonenal or
malondialdehyde decreases platelet serotonin
secretion without affecting platelet aggregability and
eicosanoid formation (vol 15, no 3)
• H Ariyoshi, A Oda, EW Salzman. Participation of
calpain in protein-tyrosine phosphorylation and
dephosphorylation in human blood platelets (vol 15,
no 4)
Vascular Biology
• AM Schmidt, O Hori, J Brett, S Du Yan, J-L Wautier,
D Stern. Cellular receptors for advanced glycation
end products: implications for induction of oxidant
stress and cellular dysfunction in the pathogenesis
of vascular lesions (vol 14, no 10)
• H-J Kruse, B Grünberg, W Siess, PC Weber.
Formation of biologically active autacoids is regu-
lated by calcium influx in endothelial cells (vol 14, no
11)
• SL Diamond, F Sachs, WJ Sigurdson. Mechanically
induced calcium mobilization in cultured endothelial
cells is dependent on actin and phospholipase (vol
14,no 12)
• KB Lemström, PT Aho, CA Bruggeman, PJ Häyry.
Cytomegalovirus infection enhances mRNA expres-
sion in platelet-derived growth factor-BB and trans-
forming growth factor-J, in rat aortic allografts:
possible mechanism for cytomegalovirus-enhanced
graft arteriosclerosis (vol 14, no 12)
• PL Walpola, AI Gotlieb, MI Cybulsky, BL Langille.
Expression of ICAM-1 and VCAM-1 and monocyte
adherence in arteries exposed to altered shear
stress (vol 15, no 1)
• F Mohamed, JC Monge, A Gordon, P Cernacek, D
Blais, DJ Stewart. Lack of role for nitric oxide (NO)
in the selective destabilization of endothelial NO
synthase mRNA by tumor necrosis factor-l (vol 15,
no1)
• TW Wakefield, RM Strieter, CA Wilke, AM Kadell,
SK Wrobleski, MD Burdick, R Schmidt, SL Kunkel,
LJ Greenfield. Venous thrombosis-associated
inflammation and attenuation with neutralizing
antibodies to cytokines and adhesion molecules (vol
15,no 2)
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• T Inaba, M Kawamura, T Gotoda, K Harada, M
Shimada, J-l Ohsuga, H Shimano, Υ Akanuma, Υ
Yazaki, N Yamada. Effects of platelet-derived growth
factor on the synthesis of lipoprotein lipase in human
monocyte-derived macrophages (vol 15, no 4)
Pathways of Blood Coagulation
• E Tremoli, S Eligini, S Colli, P Maderna P Rise, F
Pazzucconi, F Marangoni, CR Sirtori, C Galli. n-3
fatty acid ethyl ester administration to healthy
subjects and to hypertriglyceridemic patients re-
duces tissue factor activity in adherent monocytes
(vol 14, no10)
• RM Epand, A Stafford, B Leon, PE Lock, EM Tytler,
JP Segrest, GM Anantharamaiah. HOL and
apolipoprotein A-1 protect erythrocytes against the
generation of procoagulant activity (vol 14, no 11)
• N Narahara, T Enden, M Wiiger, H Prydz. Polar
expression of tissue factor in human umbilical vein
endothelial cells (vol 14, no 11)
• N Saha, Υ Liu, CK Heng, S Hong, PS Low, FSH Tay.
Association of Factor VII genotype with plasma
Factor VII activity and antigen levels in healthy
Indian adults and interaction with triglycerides
(vol 14, no12)
• U Orvim, HE Roald, RW Stephens, N Roos,
KJ Sakariassen. Tissue factor-induced coagulation
triggers platelet thrombus formation äs efficiently äs
fibrillar collagen at arterial blood flow conditions
(vol 14, no12)
• RM Barstad, MJAG Hamers, P Kierulf, Ä-B Westvik,
KJ Sakariassen. Procoagulant human monocytes
mediate tissue factor/Factor Vlla-dependent platelet-
thrombus formation when exposed to flowing
nonanticoagulated human blood (vol 15, no 1)
• BJ Warn-Cramer, Sl Rapaport. Evidence suggestive
of activation of the intrinsic pathway of blood coagu-
lation after injection of Factor Xa/phospholipid into
rabbits (vol 15, no 1)
• Sakata T, Kario K, Matsuo T, Katayama Y,
Matsuyama T, Kato K, Miyata T. Suppression of
plasma-activated Factor VII levels by warfarin
therapy (vol 15, no 2)
• T Kokawa, T Abumiya, T Kimura, M Harada-Shiba,
H Koh, M Tsushima, A Yamamoto, H Kato. Tissue
factor pathway inhibitor activity in human plasma:
measurement of lipoprotein-associated and free
forms in hyperlipidemia (vol 15, no 4)
Plasminogen Activator and Plasminogen
Activator Inhibitor
• HAR Stringer, P van Swieten, HFG Heijnen, JJ Sixma,
H Pannekoek. Plasminogen activator inhibitor-1
released from activated platelets plays a key role in
thrombolysis resistance: Studies with thrombi
generated in the Chandler loop (vol 14, no 9)
• T Padro, PHA Quax, CM van den Hoogen, P Roholl,
JH Verheijen, JJ Emeis. Tissue-type plasminogen
activator and its inhibitor in rat aorta: effect of
endotoxin (vol 14, no 9)
• M Margaglione, G Di Minno, E Grandone,
G Vecchione, E Celentano, G Cappucci, M Grilli,
P Simone, S Panico, M Mancini. Abnormally high
circulation levels of tissue plasminogen activator and
plasminogen activator inhibitor-1 in patients with a
history of ischemic stroke (vol 14, no 11)
• LM Szymanski, RR Pate. Fibrinolytic responses to
moderate intensity exercise: comparison of physi-
cally active and inactive men (vol 14, no 11)
• H Noda-Heiny, A Daugherty, BE Sobel. Augmented
urokinase receptor expression in atheroma (vol 15,
no 1)
• X-N Li, VK Varma, JM Parks, RL Benza, JC Koons,
JR Grammer, H Grenett, EM Tabengwa, FM Booyse.
Thrombin decreases the urokinase receptor and
surface-localized fibrinolysis in cultured endothelial
cells (vol 15, no 3)
Experimental Models of Thrombosis
• A Gast, TB Tschopp, HR Baumgartner. Thrombin
plays a key role in late platelet thrombus growth and/
or stability: effect of a specific thrombin inhibitor on
thrombogenesis induced by aortic subendothelium
exposed to flowing rabbit blood (vol 14, no 9)
• RM Barstad, HE Roald, Υ Cui, VT Turitto,
KJ Sakariassen. A perfusion chamber developed to
investigate thrombus formation and shear profiles in
flowing native human blood at the apex of well-
defined stenoses (vol 14, no 12)
Prothrombotic Risk Factors
• RS Rosenson, CG Tangney, JM Hafner.
Intraindividual variability of fibrinogen levels and
cardiovascular risk profile (vol 14, no 12)
• J Emmerich, D Vidaud, M Alhenc-Gelas, G Chadeuf,
M Gouault-Heilmann, M-F Aillaud, M Aiach.Three
novel mutations of antithrombin inducing high-
molecular-mass compounds (vol 14, no 12)
• SE Humphries, S Ye, P Talmud, L Bara,
L Wilhelmsen, L Tiret (European Atherosclerosis
Research Study group). European Atherosclerosis
Research Study: Genotype at the fibrinogen locus
(G
 455-A J-gene) is associated with differences in
plasma fibrinogen levels in young men and women
from different regions in Europe: Evidence for
gender-genotype-environment interaction
(vol 15, no1)
• CA Spek, T Koster, FR Rosendaal, RM Bertina,
PH Reitsma. Genotypic Variation in the promoter
region of the protein C gene is associated with
plasma protein C levels and thrombotic risk
(vol 15, no2)
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New Antithrombotic Agents
• J Strony, A Song, L Rusterholtz, B Adelman.
Aurintricarboxylic acid prevents acute rethrombosis in
a canine model of arterial thrombosis (vol 15, no 3)
Jack J. Hawiger, MD, PhD
Agenda for Thrombosis Council Program at ASH Meeting
The program for the session to be jointly sponsored by
the Thrombosis Council of the American Heart Associa-
tion and the American Hematology Society at this year's
meeting in Seattle is shown below. The Speakers will
give a 30-minute lecture that will be followed by a
question-and-answer session on Saturday, December 2,
beginning at 4:15. It will be cochaired by Sam Rapaport
and Steve Prescott.
Staying in Control: Plasma Proteins That Regulate
Thrombosis and Inflammation
Platelet-Activating Factor Acetylhydrolase:
An Anti-lnflammatory Phospholipase
Stephen M. Prescott, MD
University of Utah
Plasma Proteins That Prevent Thrombosis: Unexpected
Interactions
Joseph P. Miletich, MD, PhD
Washington University
Thermolabile Serpin Protease Inhibitor Mutants:
Thrombotic and Inflammatory Consequences
Mark Wardell, PhD
University of Cambridge MRC Centre
Report From the Program Committee
Dr Prescott reported that the Program Committee will
meet in Fall 1995 to begin planning the National
Thrombosis Conference to be held in conjunction with
the 1996 Scientific Sessions of the AHA. He encouraged
the committee members to submit suggestions for
program topics and Speakers.
He also reported that the number of evening sessions
will be decreased and the selection of Speakers will be
coordinated to eliminate overlap. It was moved,
seconded, and carried to continue to Sponsor Sunday
afternoon programs on topics attractive to broader
communities.
Stephen M. Prescott, MD
Budget Report
Dr Rapaport reported that the Council will have $19,060
in new discretionary funds for fiscal year 1995-1996 plus
any unexpended funds from fiscal year 1994-1995. It
was moved, seconded, and carried to approve the
discretionary budget for fiscal year 1995-1996:
Membership recruitment
Newsletter
Intercouncil working groups
Young Investigator Prizes
Thrombosis travel stipends
$2,000.00
4,000.00
1,500.00
N/A
N/A
Arteriosclerosis/Thrombosis/
Vascular Biology Conference 5,000.00
Gordon Conf. on Hemostasis 4,000.00
Integration Initiative 1.000.00
Total $17,500.00
It was moved, seconded, and carried to defer increasing
the monetary award for the Thrombosis Young Investiga-
tor Prize until a final decision and details of amalgam-
ation with the Council on Arteriosclerosis and the Work-
ing Group on Vascular Biology are made.
Samuel I. Rapaport, MD
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Annoimcements
Joint Conference on Arteriosclerosis/
Thrombosis/Vascular Biology
February 18-20, 1996. Salt Lake City, Utah.
Sponsored by the Councils on Arteriosclerosis and
Thrombosis and the Intercouncil Working Group on
Vascular Biology.
This Conference will bring together scientists from
atherosclerosis, thrombosis, and vascular biology to
discuss the interrelationships of their areas of research
and to provide Information on the latest advances in
these areas. Emphasis will be given to modern tech-
nologies involving molecular genetics.
Abstracts for this Conference are due Friday,
November 17,1995. For more Information, call 214-
706-1100, fax 214-373-3406, or write to the American
Heart Association, Scientific and Corporate Meetings,
7272 Greenville Avenue, Dallas, TX 75231-4596.
TRIGGER: An Electronic Newsletter
for Researchers Working on the
Biology of Tissue Factor and Factor
VII
An electronic newsletter has been started to facilitate
communication among researchers working on the
biology of the triggering complex of the blood clotting
System (tissue factor and factor VII). TRIGGER will
carry titles and brief descriptions (or abstracts) of papers
recently accepted for publication, meeting announce-
ments and reports, positions available, technical ques-
tions, etc. The newsletter will be sent via e-mail.
For more Information (including how to subscribe),
send a message with your preferred e-mail address to
trigger@omrf.uokhsc.edu. Information can also be
obtained via the World Wide Web at http://
omrf.uokhsc.edu/~trigger/or by contacting either James
H. Morrissey (morrisseyj@omrf.uokhsc.edu) or Pierre F.
Neuenschwander (pierren@omrf.uokhsc.edu) at the
Oklahoma Medical Research Foundation, 825 NE 13th
Street, Oklahoma City, OK 73104. Tel 405-271-7892.
Fax 405-271-3137.
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Application for
Membership
Council on
Thrombosis
Council dues are $25/year
The purpose of the council is to achieve the
objectives of the AHA in the field of thrombosis,
specifically äs they relate to research, Professional
education, and the application of these matters to
clinical science. A chief objective is to view
thrombosis in all its ramifications, rather than solely
through its effect on the heart, brain, and kidney.
The council conducts postgraduale seminars
and scientific sessions, either separately or in coop-
eration with other scientific councils. It also assists in
development of educational materials, evaluates
medical Knowledge with respect to its application in
controlling thrombosis, and collaborates with other
councils in areas of mutual concern and interest.
Council members represent a large number of
disciplines, enabling a forum for eventual Solutions to
the problems of thrombosis at all levels—basic
research, clinical investigation, community health
Problems, and public understanding.
This offer expires December 31, 1995
Please mail completed form along with payment to:
American Heart Association
Scientific Publishing
PO Box 843543
Dallas, TX 75284-3543
OR
fax credit card Orders to
214-691-6342
Questions?
Call 214-706-1310 or 214-706-1201
Please share this with interested colleagues
5NEWS1/2
Name
JYES! l want to join the Council on Thrombosis.
Address_
City/State/Postal Code_
Country
Telephone_ .Fax.
E-Mail Address
Month and Year of Birth
Race/Ethnicity:
D American Indian
D Asian
D Black
D Hispanic
O White
/ Gender:
% of time spent (=1 00%):
Administrative
Patient Gare
Research
Teaching
Other (specify)
D M D F
Are you interested in Vascular Biology? D Yes D No
Specialty
JYES! As an AHA Council Member, l want to
subscribe at these special prices.
United States Outside US
Non- Non-
Member Member Member Member
D Arteriosclerosis, Thrombosis,
and Vascular Biology $109 .... $146 $145 $182
G Cardiovascular Nursing 6 6 15 15
D Circulation 101 135 203 237
D Circulation Research 128 171 194 237
D Currents in Emergency Cardiac Care... 12 12 16 16
Π Hypertension 101 135 141 175
D Stroke 101 135 155 189
Please Start my subscription with the. issue
ADVANCE PAYMENT REQUIRED
D Check or money order enclosed (payable to the American Heart
Association drawn on US bank in US dollars)
D MasterCard
Card Number
D Visa D American Express
Expirationdate.
Signatare äs it appears on card:
Total payment $_
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AHA Services
Το provide you with the best
customer Service, listed below are the
Services and contact numbers you are
most likely to need.
To ensure timely delivery of your
newsletter, Journals, and other impor-
tant Information, please send us your
address changes and phone and fax
numbers using the coupon below.
AHA National Center
7272 Greenville Avenue
Dallas,TX75231-4596
Tel 214-373-6300 Fax 214-691-6342
gopher.amhrt.org
Service
Address Changes
Awards
Council New Investigator Award
Research Award
Student Scholarship (Council)
Conferences
Annual Scientific Sessions
Scientific Conferences
Council Membership
Applications — Catalog
Billing Information
Donations/Memorials
Journals
Advertising
Billing Information
Permissions
Reprints
Subscriptions — Catalog
Publications
Public/Patient Education
Scientific Statements
Department
Customer Service
Meetings
Research Administration
Scientific Councils
Meetings
Meetings
Customer Service
Customer Service
Finance
Scientific Publishing
Customer Service
Scientific Publishing
Scientific Publishing
Customer Service
Local AHA Offices
Inquiries
Telephone
214-706-1310 or 1201
214-706-1685
214-706-1453
214-706-1476 or 1261
214-706-1253
214-706-1511 or 1414
214-706-1201
214-706-1310 or 1201
214-706-1417
214-706-1426
214-706-1310
214-706-1309 or 1313
214-706-1466
214-706-1310
800-242-8721
214-706-1220
Fax
214-691-6342
214-373-3406
214-706-1341
214-373-0268
214-373-3406
214-373-3406
214-691-6342
214-691-6342
214-368-1228
214-691-6342
214-691-6342
214-691-6342
214-691-6342
214-691-6342
214-706-1341
E-Mail
pubcust@amhrt.org
daphner® amhrt.org
pubcust@amhrt.org
pubcust@amhrt.org
pubcust@amhrt.org
pubauth@amhrt.org
pubauth@amhrt.org
pubcust@amhrt.org
MOVING?
Please print your new address below:
Name
Address
City State/Province/Country Zip/Post Code
Phone Fax
E-mail
Moving date
IMPORTANT!
ATTACH ADDRESS LABEL HERE
Clip this form including your mailing label and send to:
AMERICAN HEART ASSOCIATION
Scientific Publishing
7272 Greenville Ave
Dallas, TX 75231-4596
Fax 214-691-6342
Tel 214-706-1310
1
American Heart
Association J
l-!'jh!:ng Henri Discnse
find StmKa
You'd use it in an
emergency.
Why not use it
to prevent one?
Some people in Washington want to slash
govcrnment funding for biomedical rcscarch.
We're fighting tbr rescarch, but we nced your help.
If you won't lift a finger for research, how can you
expect anyone eise to?
WhiteHouseCommentLine: (202)456-1111-CapitolSwitchboard: (202)224-3121-PresidentClinton'se-mail: prcsident@whitehouse.gov
Research Funding. Talk it up.
